Transparency vs. Smoke and Mirrors: Clinical Trials Debate

December 22, 2015 Peter J. Pitts

 

broken-mirror.jpg

The debate around clinical trial transparency is certainly nothing new. But is the answer, as some call for, "more transparency and oversight?"

I say it’s just not that simple.

As the former senior government official in charge of clinicaltrials.gov, I think it’s important to look at the facts – and the numbers.  When it comes to the clinical trial looking glass, smart transparency must replace the smoke and mirrors currently in vogue.

Read my full article in the The Morning Consult, where I ask key questions and examine critical issues surrounding the debate. 

Be sure to read on about different clinical trial best practices in the YourEncore Thought Leadership blog.

Peter J. Pitts. Executive Partner for YourEncore, President - Center for Medicines in the Public Interest, Former FDA Associate Commissioner.

Watch the Regulatory Convergence & Divergence Expert Panel Discussion

 

Previous Article
YourEncore Insights Greatest Hits of 2015

Billboard recently released its “Hot 100 Songs of 2015,” and it inspired me to think about YourE...

Next Article
BioMarin Advisory Committee Outcome - Canary in the Coal Mine?
BioMarin Advisory Committee Outcome - Canary in the Coal Mine?

The FDA recently held an Advisory Committee meeting to consider BioMarin’s investigatory treatment for Duch...